Once again, Paxman will be exhibiting at the ESMO/EONS Annual Congress, one of the world's leading events for the oncology community. Bringing together clinicians, researchers, patient advocates and industry representatives, the congress provides a unique opportunity to explore the latest developments in cancer care, including innovations in chemotherapy side-effect management.
Taking place in Madrid, this year's congress will shine a spotlight on the latest scientific discoveries, clinical advancements and patient-centred approaches, creating opportunities to share knowledge, build connections and inspire progress across the oncology landscape.
Chemotherapy-induced peripheral neuropathy (CIPN) remains a significant unmet need in cancer care, often permanently affecting patients long after treatment and impacting both quality of life and daily functioning.
This 45-minute symposium will showcase the latest developments in the prevention and management of chemotherapy-induced peripheral neuropathy (CIPN), bringing together leading experts to discuss unmet patient needs, current clinical practice, and the future of side effect management in patient-centred cancer care.
Attendees will gain early access to the latest Phase 2 clinical data investigating cryocompression for CIPN prevention, highlighting the potential of this innovative approach to tackling one of the most challenging side effects of cancer treatment. The session will also introduce the groundbreaking Paxman Neuropathy device, a major innovation set to redefine side effect management in cancer care.
Dr Mary Tanay is a Macmillan Nurse Consultant in Berkshire Cancer Centre, Royal Berkshire NHS Foundation Trust and Honorary Senior Lecturer at the Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King’s College London. She is also a member of the Advocacy Working Group of the European Oncology Nursing Society.
Her research interests are supportive care in cancer, co-design methodology, workforce and patient education, and lived patient experience of cancer with focus on chemotherapy-induced peripheral neuropathy. For her National Institute for Health and Care Research-funded doctoral project, she co-designed with patients and clinicians a behavioural intervention to mitigate the effects of CIPN.
Megan Pritchard is Deputy Chief Nursing Officer for Cancer at HCA Healthcare UK, providing senior nursing leadership across inpatient, outpatient and clinical trial services, including Sarah Cannon Research Institute UK. She has extensive experience in the delivery of systemic anti-cancer treatment and the management of patients receiving complex cancer therapies across a range of clinical settings.
Megan has a particular interest in improving the quality and safety of cancer care, supporting patients to manage treatment-related toxicities and translating evidence into high-quality clinical practice. Her experience spans clinical leadership, service improvement, governance, workforce development and clinical research, with a strong focus on delivering patient-centred cancer care. She holds an Executive Master’s in Leadership from Bayes Business School, awarded with distinction.
Chris has been a consultant treating people with cancer for over 30 years with a particular interest in new drug development and clinical pharmacology.
His first degree was in Experimental Medicine and Pharmacology and after completing his medical degree in Sheffield he trained as a medical oncologist in London.
As a Consultant, Chris was Senior Lecturer, then Reader, in Medical Oncology at Glasgow’s Beatson Oncology Centre before taking up his current post at the University of Leeds and Leeds Teaching Hospitals NHS Trust.
Chris has been involved in the development of several important new cancer drugs used routinely in the clinic and has published around 300 papers as well as speaking at innumerable national/international meetings.
He was Deputy Director of the CR UK Leeds Centre, led the CR UK Leeds Experimental Cancer Medicine Centre and for over 10 years has been Director of the NIHR Leeds Clinical Research Facility.
Maryam Lustberg MD MPH is a breast medical oncologist and currently serves as Chief of Breast Oncology and Director of the Breast Center at Yale Cancer Center in New Haven Connecticut. She is the co-chair of Symptom Intervention for the USA National Cancer Institute Alliance Clinical Trials and is a Past President of MASCC, an international organization devoted to improving cancer supportive care throughout the globe.
Her research is centered on biomarkers of therapeutic response and toxicity as well as cancer treatment symptom management and survivorship care optimization, with a focus on chemotherapy neuropathy.
Discover the latest innovations in side effect management in cancer care and be among the first to experience Paxman's new cryocompression technology to manage chemotherapy-induced peripheral neuropathy (CIPN)..
With more than 25 years of leadership in chemotherapy side effect management, Paxman continues to set the standard in helping prevent chemotherapy-induced alopecia and is now bringing the same commitment to innovation to the management of CIPN.
Visitors to our booth will have the opportunity to take a first look at the Paxman Neuropathy, our new cryocompression technology, designed to help manage chemotherapy-induced peripheral neuropathy.
We're offering a limited number of pre-booked demonstration slots so you can explore the new CIPN technology with our experts. Register your interest today and be among the first to see it in action.
Head of International Sales
Regional Representative - Spain
Events Manager
Regional Manager LATAM & ASEAN
Head of Brand and Marketing
Head of UK Sales and Training
